Heart surgery without a heart-lung machine - 18/11/2026 HeartGate: the safe gateway to the heart For patients with advanced heart failure, a mechanical heart pump can offer a life-saving alternative to heart transplants. As part of the HeartGate project, researchers at the University Medical Center Freiburg are developing an innovative implantation system to insert a heart pump directly into a beating heart. https://www.gesundheitsindustrie-bw.de/en/article/news/heartgate-safe-gateway-heart
Press release - 17/11/2026 When Brake Cells Become Killer Cells: Double Honor for DKFZ Researcher Julius Michel Julius Michel, a postdoctoral researcher at the German Cancer Research Center, has received two awards: the Craig Tendler Award for Myeloma Research from the American Society of Hematology - awarded for the first time and accompanied by a $10,000 prize - as well as another award from the society.https://www.gesundheitsindustrie-bw.de/en/article/press-release/when-brake-cells-become-killer-cells-double-honor-dkfz-researcher-julius-michel
Press release - 12/11/2026 DKFZ Sets Records for ERC Synergy Grants A historic success for the German Cancer Research Center (DKFZ): Four DKFZ researchers are receiving one of the prestigious ERC Synergy Grants this year—more than ever before at a single institution in a single funding round. Three of the four international research consortia are coordinated by the DKFZ. In total, the projects will receive approximately 44.5 million euros, of which about 13.7 million euros will go to the DKFZ.https://www.gesundheitsindustrie-bw.de/en/article/press-release/dkfz-sets-records-erc-synergy-grants
Press release - 11/11/2026 Spine tumor surgery: Better preparation with a digital twin How can complex spinal tumor surgeries be planned and prepared more effectively in the future? As part of the IntelliSpine-Recon collaborative project, researchers will develop, among other innovations, a digital twin of the spine and a virtual training environment for surgeons. The junior research consortium, coordinated by the Heidelberg Faculty of Medicine at Heidelberg University, is being carried out in partnership with the KIT. https://www.gesundheitsindustrie-bw.de/en/article/press-release/spine-tumor-surgery-better-preparation-digital-twin
Press release - 09/11/2026 Mirco Friedrich Receives the Peter and Traudl Engelhorn Foundation Award Mirco Julian Friedrich, a physician and cancer researcher at the German Cancer Research Center (DKFZ), the HI-STEM* Stem Cell Research Institute, and Heidelberg University Hospital (UKHD), is being honored for his outstanding research on the aging immune system and the immune response to blood cancer.https://www.gesundheitsindustrie-bw.de/en/article/press-release/mirco-friedrich-receives-peter-and-traudl-engelhorn-foundation-award
Press release - 02/11/2026 Stem Cells in Deep Sleep as a Secret Reserve Researchers at the German Cancer Research Center (DKFZ) and the HI-STEM* Stem Cell Institute have discovered a group of particularly long-lived blood stem cells in mice. These cells remain in a dormant state for an exceptionally long time while retaining their ability to generate new blood cells. This newly discovered cell population may be responsible for sustaining blood regeneration and immune defense throughout a mouse’s entire life.https://www.gesundheitsindustrie-bw.de/en/article/press-release/stem-cells-deep-sleep-secret-reserve
Press release - 29/10/2026 New Approach Could Make Immunotherapy for Blood Cancer More Precise Researchers at the Faculty of Medicine – University of Freiburg have developed a new approach to specifically target an aggressive form of blood cancer while better sparing healthy immune cells. In what is known as T-cell acute lymphoblastic leukemia (T-ALL), cancer cells develop from the body’s own immune defense cells. This complicates treatment, as immunotherapies studied to date can also destroy healthy immune cells.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approach-could-make-immunotherapy-blood-cancer-more-precise
Press release - 28/10/2026 A Discovery in Freiburg Makes Cancer Immunotherapy Better Tolerated A discovery made in Freiburg opens up new treatment options for cancer patients worldwide: Researchers at the Medical Center – University of Freiburg have discovered how severe side effects of cancer immunotherapies can be alleviated using a specialized cell therapy involving treated white blood cells.https://www.gesundheitsindustrie-bw.de/en/article/press-release/discovery-freiburg-makes-cancer-immunotherapy-better-tolerated
Press release - 16/10/2026 A new approach to osteoporosis treatment Disabling a bone formation inhibiting protein molecule How can the human body be stimulated to build more bone, thus helping those affected by osteoporosis? Researchers in Ulm have investigated the role played by the protein molecule Axl in this process. Their efforts were successful: in a study, they demonstrated that Axl inhibits bone formation – and that cells produce significantly more bone tissue when the molecule is blocked using medication. There are no discernible harmful side effects. https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approach-osteoporosis-treatment-disabling-bone-formation-inhibiting-protein-molecule
Press release - 06/10/2026 Harnessing Synthetic Cellular Systems as Immune Cell Boosters How can cell-based immunotherapies for cancer and autoimmune diseases become more widely available in the long term? The SYNTHIA project is addressing this challenge: The Max Planck Institute for Medical Research and the Fraunhofer Institute for Cell Therapy and Immunology IZI are collaborating on new research approaches to advance the development of cell-based immunotherapies.https://www.gesundheitsindustrie-bw.de/en/article/press-release/harnessing-synthetic-cellular-systems-immune-cell-boosters
Press release - 05/10/2026 A Matter of Quantity: A Universal Target for CAR-T Cells Against Cancer CAR-T cell therapies have proven successful in treating several types of blood and lymphoid cancers. However, their use in treating other tumors is significantly more challenging, in part because suitable target structures are lacking.https://www.gesundheitsindustrie-bw.de/en/article/press-release/matter-quantity-universal-target-car-t-cells-against-cancer-1
Press release - 05/10/2026 A Matter of Quantity: A Universal Target for CAR-T Cells Against Cancer CAR-T cell therapies have proven successful in treating several types of blood and lymphoid cancers. However, their use in treating other tumors is significantly more challenging, in part because suitable target structures are lacking.https://www.gesundheitsindustrie-bw.de/en/article/press-release/matter-quantity-universal-target-car-t-cells-against-cancer
Press release - 05/10/2026 How blood flow controls liver function The liver is organized into distinct zones in which liver cells perform different functions. The blood vessels of the liver play an important role in this spatial organization: the endothelial cells lining the vessels provide signals that instruct neighboring liver cells and help determine their function. But how do endothelial cells know which signals to produce?https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-blood-flow-controls-liver-function
Use of health data - 22/09/2026 The digital twin – shaping the future of neonatal medicine Virtually every newborn undergoes routine screening shortly after birth to detect congenital disorders. These examinations have generated a unique wealth of data on early childhood development. However, for many years this valuable resource remained largely untapped. That all changed when researchers in Heidelberg started to use the data to develop a digital twin for newborns. Today, the technology is on the verge of entering clinical practice.https://www.gesundheitsindustrie-bw.de/en/article/news/digital-twin-shaping-future-neonatal-medicine
Press release - 17/09/2026 New technique could make MRI more precise A team of researchers at the University of Stuttgart has developed a new method that could make MRI even more precise by eliminating “dead time,” a key limiting factor in the measurement process, thereby enabling the detection of signals that are lost using conventional methods. This method opens up new possibilities for medical diagnostics and non-destructive materials testing. The research team presents the new approach in Science Advances.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-technique-could-make-mri-more-precise
Press release - 08/09/2026 Quality Over Quantity: New Insights into the Role of Specific CAR T Cells in Cancer Therapy CAR T-cell therapies are used successfully to treat certain blood cancers. However, while some patients respond even to low-dose treatment, others derive no benefit. Researchers from the Heidelberg Faculty of Medicine at Heidelberg University and the Berlin Institute of Health at Charité (BIH) investigated the reasons behind these differences in a collaborative research project.https://www.gesundheitsindustrie-bw.de/en/article/press-release/quality-over-quantity-new-insights-role-specific-car-t-cells-cancer-therapy
Press release - 01/09/2026 Early Detection of COPD: A Study in Freiburg Investigates a New Treatment Coughing, phlegm, and shortness of breath can be early signs of COPC. In COPD, the airways are permanently narrowed, making it harder to breathe. The most significant risk factor is long-term smoking. The CHRONOS study conducted by the Department of Pneumology at the Medical Center – University of Freiburg provides evidence that changes in the lungs can already be detected before a standard pulmonary function test confirms the airway narrowing.https://www.gesundheitsindustrie-bw.de/en/article/press-release/early-detection-copd-study-freiburg-investigates-new-treatment
Press release - 13/08/2026 PRAME-specific T-cell therapy in an adolescent with metastatic kidney tumor Researchers and physicians at the Hopp Children's Cancer Center Heidelberg (KiTZ) and other leading cancer centers report an exceptional treatment success in an adolescent with an advanced, therapy-resistant kidney tumor. Using a novel, personalized T-cell therapy, they succeeded in completely pushing back the tumor disease despite multiple metastases.https://www.gesundheitsindustrie-bw.de/en/article/press-release/prame-specific-t-cell-therapy-adolescent-metastatic-kidney-tumor
Press release - 10/08/2026 Immune Cells in Bone Marrow Cancer: Limited Defense Readiness A team led by researchers from the German Cancer Research Center, the HI-STEM* Stem Cell Institute, and Medical Clinic V at Heidelberg University Hospital has characterized T cells in the bone marrow in cases of multiple myeloma and acute myeloid leukemia: A specific group of tumor-reactive T cells can recognize and fight cancer cells, but is often not sufficiently activated. Nevertheless, the number of these cells influences the prognosis.https://www.gesundheitsindustrie-bw.de/en/article/press-release/immune-cells-bone-marrow-cancer-limited-defense-readiness
Press release - 07/08/2026 Can Protein Building Blocks Protect Against Vascular and Kidney Damage? Researchers from the Medical Faculty Heidelberg, the Medical Faculty Mannheim, and the Centre for Organismal Studies at Heidelberg University have launched a new research project investigating so-called dipeptides. The consortium aims to determine which dipeptides have the strongest protective effects and how they could be harnessed in future therapies for vascular and kidney diseases.https://www.gesundheitsindustrie-bw.de/en/article/press-release/can-protein-building-blocks-protect-against-vascular-and-kidney-damage
Press release - 31/07/2026 New insights into Malaria research: How molecular tethers and Asynchronous replication drive parasite proliferation Researchers from Heidelberg University’s Faculty of Medicine, Harvard Medical School, and the German Cancer Research Center (DKFZ) have uncovered key mechanisms underlying the proliferation of the malaria parasite Plasmodium. The molecular processes that govern the formation of infectious daughter parasites and new nuclei are essential for parasite survival and may therefore represent targets for future antimalarial therapies.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-insights-malaria-research-how-molecular-tethers-and-asynchronous-replication-drive-parasite-proliferation
Press release - 20/07/2026 Blood vessels guide immune cells to metastases It has long been suspected that endothelial cells play a key role in determining how the body’s immune system responds to tumors. Researchers at the DKFZ and the Medical Faculty Mannheim of Heidelberg University have now identified, in mouse studies, a specialized population of blood vessel lining endothelial cells that enable an effective immune defense against cancer metastases in the liver. https://www.gesundheitsindustrie-bw.de/en/article/press-release/blood-vessels-guide-immune-cells-metastases
Press release - 16/07/2026 New Findings on Acute Leukemias: Specific Mutations Provide Targets for More Targeted Therapies Researchers at the NCT Heidelberg and the German Cancer Research Center (DKFZ) have, for the first time, systematically determined how specific mutations promote acute myeloid leukemias. The results show why IDH1- and IDH2-mutated leukemias develop differently despite similar molecular mechanisms—and open up new approaches for diagnostics and targeted therapies. https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-findings-acute-leukemias-specific-mutations-provide-targets-more-targeted-therapies
CRISPR base editing for tailored tumour treatment - 16/07/2026 Targeted genetic manipulation of signal transduction pathways in CAR T cells enhances anti-tumour potency Chimeric antigen receptor (CAR) T cell therapy has emerged as a highly promising treatment modality but has so far been used almost exclusively for advanced haematologic malignancies. Researchers at the iFIT cluster of excellence in Tübingen have now used CRISPR base-editing technology to introduce precise point mutations into key signalling pathways of CAR T cells, significantly enhancing their long-term persistence and anti-tumour potency.https://www.gesundheitsindustrie-bw.de/en/article/news/targeted-genetic-manipulation-signal-transduction-pathways-car-t-cells-enhances-anti-tumour-potency
Press release - 14/07/2026 Steering the Formulation of Engineered Tissue by Sound Waves With the aid of physical forces it is possible to actively steer the formation of engineered tissue. For example, sound waves can be used to create functional vascular networks with blood vessel-like structures in vitro. Scientists at the Center for Molecular Biology of Heidelberg University have demonstrated this through their methodology for acoustic manipulation. https://www.gesundheitsindustrie-bw.de/en/article/press-release/steering-formulation-engineered-tissue-sound-waves